Gene expression profile of multiple myeloma cell line treated by arsenic trioxide

Abstract

cDNA microarray was used to compare the gene expression profiles of multiple myeloma cell line RPMI8226 24 h before and after treatment with arsenic trioxide. Two cDNA probes were prepared by mRNA reverse transcription of both arsenic trioxide-treated and untreated RPMI8226 cells. The probes were labeled with Cy3 and Cy5 fluorescence dyes separately, hybridized with cDNA microarray representing 4096 different human genes, and scanned for fluorescence intensity. The differences in gene expression were calculated on the basis of the ratios of signal intensity of treated and untreated samples. The up-and down-regulated genes were screened through the analysis of gene expression ratios. The results showed that 273 genes were differentially altered at mRNA level, 121 genes were up-regulated and 152 were down-regulated. It is concluded that the treatment with arsenic trioxide can induce a variety of gene changes in RPMI8226 cell line. Many genes may be involved in the pathogenesis of multiple myeloma. ALK-1 and TXNIP genes may play an important role in the apoptosis and partial differentiation of RPMI8226 cells.

Keywords

multiple myeloma / gene expression / arsenicals / arsenic trioxide

References

[1] DaltonW. S.. Targeting the mitochondria: an exciting new approach to myeloma therapy. Clin Cancer Res, 2002, 8(12): 3643-3645

[2] BahlisN. J., McCafferty-GradJ., Jordan-McMurryI., et al.. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res, 2002, 8(12): 3658-3668

[3] PanditS., VesoleD. H.. Relapsed multiple myeloma. Curr Treat Options Oncol, 2001, 2(3): 261-269

[4] SoignetS. L., MaslakP., WangZ. G., et al.. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med, 1998, 339: 1341-1348

[5] SoignetS. L., FrankelS. R., DouerD., et al.. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol, 2001, 19: 3852-3860

[6] GradJ. M., BahlisN. J., ReisI., et al.. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood, 2001, 8(3): 805-813

[7] JiaP., ChenG., HuangX., et al.. Arsenic trioxide induces multiple myeloma cell apoptosis via disruption of mitochondrial transmembrane potentials and activation of caspase-3. Chin Med J (Engl), 2001, 114(1): 19-24

[8] SeetL. F., HongW.. Endofin, an endosomal FYVE domain protein. J Biol Chem, 2001, 276(45): 42445-42454

[9] SeetL. F., LiuN. S., BrendonJ., et al.. Endofin recruits TOM1 to endosomes. J Biol Chem, 2004, 279(6): 4670-4679

[10] SeetL. F., HongW.. Endofin recruits clathrin to early endosomes via TOM1. J Cell Sci, 2005, 118: 575-587

[11] GrandF. H., BurgstallerS., KuhrT., et al.. P53-binding protein 1 is fused to the platelet-derived growth factor receptor in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. Cancer Res, 2004, 64(20): 7216-7219

[12] IwabuchiK., BartelP. L., LiB., et al.. Two cellular proteins that bind to wild-type but not mutant p53. Proc Natl Acad Sci USA, 1994, 91: 6098-6102

[13] IwabuchiK., LiB., MassaH. F., et al.. Stimulation of p53-mediated transcriptional activation by the p53-binding proteins, 53BP1 and 53BP2. J Biol Chem, 1998, 273: 26061-26068

[14] DerbyshireD. J., BasuB. P., SerpellL. C., et al.. Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor. EMBO J, 2002, 21: 3863-3872

[15] HuiT. Y., ShethS. S., DiffleyJ. M., et al.. Mice lacking thioredoxin-interacting protein provide evidence linking cellular redox state to appropriate response to nutritional signals. J Biol Chem, 2004, 279(23): 24387-24393

[16] DerooB. J., HewittS. C., PeddadaS. D., et al.. Estradiol regulates the thioredoxin antioxidant system in the mouse uterus. Endocrinology, 2004, 145(2): 5485-5492

[17] JiaP., ChenG., HuangX., et al.. Arsenic trioxide induces multiple myeloma cell apoptosis via disruption of mitochondrial transmembrane potentials (delta psi m)collapse and activation of caspase-3. Chin Med J (Engl), 2001, 114(1): 19-24

[18] BergJ. N., GallioneC. J., StenzelT. T., et al.. The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2. Am J Hum Genet, 1997, 61(1): 60-67

[19] SekiT., YunJ., OhS. P.. Arterial endothelium-specific activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling. Circ Res, 2003, 93(7): 682-689

[20] GoumansM. J., ValdimarsdottirG., ItohS., et al.. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell, 2003, 12(4): 817-828

[21] SilvermanG. A., KuoW. L., Taillon-MillerP., et al.. Chromosomal reassignment: YACs containing both YES1 and thymidylate synthase map to the short arm of chromosome 18. Genomics, 1993, 15(2): 442-445

[22] SukegawaK., SugawaraI., SugawaraJ., et al.. Distribution of c-YES1 gene product in various cell and tissues. Br J Cancer, 1991, 63: 508-513

[23] ParkJ., MeislerA. I., CartwrightC. A.. C-Yes tyrosine kinase activity in human colon carcinoma. Oncogene, 1993, 8(10): 2627-2635

[24] ContiI., RollinsB.. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol, 2004, 14: 149-154